ABVC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
796.0K
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
796.0K
0
Operating Expenses
779.5K
-50.4%
1.6M
2.0M
-14.4%
2.3M
R&D
22.7K
-31.4%
33.1K
29.9K
-10.2%
33.3K
SG&A
756.8K
+0.6%
752.0K
798.3K
-64.7%
2.3M
Operating Income
-779526
+50.4%
-1572472
-1168410
+49.1%
-2294983
EBITDA
-773010
+50.7%
-1566689
-27153.9%
5.8K
+100.5%
-1162589
+49.2%
-2288286
Net Income
-810481
+52.0%
-1689937
-1287523
+44.8%
-2332833
EPS (Basic)
$-0.03
+50.0%
$-0.06
$-0.05
+61.5%
$-0.13
EPS (Diluted)
$-0.03
+50.0%
$-0.06
$-0.05
+61.5%
$-0.13
Shares (Diluted)
26.1M
+2.4%
25.4M
+2.5%
24.8M
+6.7%
23.3M
+33.8%
17.4M
ABVC BioPharma (ABVC) — Financials